Marker Therapeutics Stock Net Income
| MRKR Stock | USD 1.53 0.02 1.32% |
Marker Therapeutics fundamentals help investors to digest information that contributes to Marker Therapeutics' financial success or failures. It also enables traders to predict the movement of Marker Stock. The fundamental analysis module provides a way to measure Marker Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Marker Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -12.6 M | -13.3 M | |
| Net Loss | -22.1 M | -23.2 M | |
| Net Loss | -37.7 M | -39.6 M | |
| Net Loss | (1.43) | (1.51) | |
| Net Income Per E B T | 0.90 | 0.79 |
Marker | Net Income |
Marker Therapeutics Company Net Income Analysis
Marker Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Marker Therapeutics Net Income | (14.05 M) |
Most of Marker Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Marker Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Marker Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Marker Therapeutics is extremely important. It helps to project a fair market value of Marker Stock properly, considering its historical fundamentals such as Net Income. Since Marker Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Marker Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Marker Therapeutics' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Marker Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Marker Therapeutics reported net income of (14.05 Million). This is 104.12% lower than that of the Biotechnology sector and 120.05% lower than that of the Health Care industry. The net income for all United States stocks is 102.46% higher than that of the company.
Marker Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Marker Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Marker Therapeutics could also be used in its relative valuation, which is a method of valuing Marker Therapeutics by comparing valuation metrics of similar companies.Marker Therapeutics is currently under evaluation in net income category among its peers.
Marker Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Marker Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Marker Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Marker Therapeutics' value.| Shares | Invst Llc | 2024-12-31 | 20.2 K | Creative Planning Inc | 2024-12-31 | 17.3 K | Blackrock Inc | 2024-12-31 | 16.6 K | Engineers Gate Manager Lp | 2024-12-31 | 16.4 K | Millennium Management Llc | 2024-12-31 | 16.1 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 15.9 K | Matrix Asset Advisors Inc | 2024-12-31 | 15 K | Citadel Advisors Llc | 2024-09-30 | 13 K | Bank Of America Corp | 2024-12-31 | 3.2 K | Nea Management Company, Llc | 2024-12-31 | 1.6 M | Alyeska Investment Group, L.p. | 2024-12-31 | 915.6 K |
Marker Fundamentals
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.42 | ||||
| Profit Margin | (1.80) % | ||||
| Operating Margin | (1.25) % | ||||
| Current Valuation | (1.74 M) | ||||
| Shares Outstanding | 10.71 M | ||||
| Shares Owned By Insiders | 9.85 % | ||||
| Shares Owned By Institutions | 41.78 % | ||||
| Number Of Shares Shorted | 232.13 K | ||||
| Price To Earning | (9.39) X | ||||
| Price To Book | 2.20 X | ||||
| Price To Sales | 3.04 X | ||||
| Revenue | 3.31 M | ||||
| Gross Profit | (5.6 M) | ||||
| EBITDA | (11.79 M) | ||||
| Net Income | (14.05 M) | ||||
| Cash And Equivalents | 18.08 M | ||||
| Cash Per Share | 0.22 X | ||||
| Total Debt | 3.07 M | ||||
| Debt To Equity | 0.34 % | ||||
| Current Ratio | 1.99 X | ||||
| Book Value Per Share | 0.83 X | ||||
| Cash Flow From Operations | (16.44 M) | ||||
| Short Ratio | 3.13 X | ||||
| Earnings Per Share | (1.09) X | ||||
| Target Price | 11.5 | ||||
| Beta | 1.44 | ||||
| Market Capitalization | 16.38 M | ||||
| Total Asset | 17.13 M | ||||
| Retained Earnings | (436.29 M) | ||||
| Working Capital | 14.05 M | ||||
| Current Asset | 6.85 M | ||||
| Current Liabilities | 5.93 M | ||||
| Net Asset | 17.13 M |
About Marker Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Marker Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Marker Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Marker Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for Marker Stock Analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.